Wedbush Initiates Coverage On Crescent Biopharma with Outperform Rating, Announces Price Target of $27
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Wedbush analyst Robert Driscoll initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Outperform rating and announces Price Target of $27.
Wedbush analyst Robert Driscoll initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Outperform rating and announces Price Target of $27.